Search

Displaying results 681 - 690 of 4265 in total
  1. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

  2. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

  3. Drug

    Eprosartan

    go.drugbank.com/drugs/DB00876
    ApprovedInvestigational

    By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.

  4. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. … [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019.

  5. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH).

  6. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256408] By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity

  7. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

  8. Drug

    Fluconazole

    go.drugbank.com/drugs/DB00196
    ApprovedInvestigational

    It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole].

  9. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518] … Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering

  10. Drug

    Paromomycin

    go.drugbank.com/drugs/DB01421
    ApprovedInvestigational

    An oligosaccharide antibiotic produced by various streptomyces. [PubChem]